Showing 1231-1240 of 5062 results for "".
- Triple Combo Acne Gel Well-tolerated in Two Studieshttps://practicaldermatology.com/news/triple-combo-acne-gel-well-tolerated-in-phase-2-study/2462194/A triple combination acne gel (IDP-126) was shown to be safe and effective in two phase 3 studies, according to a new analysis. Researchers publishing
- Vidac Queues Up Phase 2b Study for Potential Actinic Keratosis Therapyhttps://practicaldermatology.com/news/vidac-pharma-to-conduct-phase-2b-study-for-actinic-keratosis-therapeutic-candidate-vda-1102-with-centroderm/2462192/Vidac Pharma Holdings recently announced the commencement of a Phase 2b trial for its candidate therapy (VDA-1102) to treat actinic keratosis (AK), and has engaged with a research team from a leading clinical dermatology clinical research institute (CentroDerm GmbH). According to the ma
- PF-07038124 Shows Safety, Efficacy for AD and Plaque Psoriasis: Studyhttps://practicaldermatology.com/news/efficacy-and-safety-of-pf-07038124-in-patients-with-atopic-dermatitis-and-plaque-psoriasis/2462191/A novel topical phosphodiesterase 4 inhibitor (PF-07038124) has been shown to be efficacious and well-tolerated in patients with atopic dermatitis (AD) and plaque psoriasis, according to new study results. Researchers writing in
- Lindus Health and Thirty Madison Complete Enrollment of Personalized Dermatology Care Pilot Studyhttps://practicaldermatology.com/news/lindus-health-and-thirty-madison-complete-enrollment-of-personalized-dermatology-care-pilot-study/2462182/Clinical trial company Lindus Health and Thirty Madison, a US-based family of specialized healthcare brands, announced the completion of enrolment of a pilot study to assess the effectiveness of their personalized dermatology telemedicine platform Facet. The novel teleh
- Scinai Announces Promising Results in a Psoriatic Human Skin Modelhttps://practicaldermatology.com/news/scinai-announces-promising-results-in-a-psoriatic-human-skin-model/2462180/Scinai Immunotherapeutics Ltd. announced a successful preclinical trial result for its anti-IL-17 VHH antibody (NanoAb) as a local treatment for moderate plaque psoriasis. The study, designed to evaluate the anti-inflammatory effects of NanoAbs, used proprietary induced human
- Kymera Update: First Patient Dosed in Phase 2 AD Clinical Trial of KT-474, a First-in-Class Investigational IRAK4 Degraderhttps://practicaldermatology.com/news/kymera-update-first-patient-dosed-in-phase-2-ad-clinical-trial-of-kt-474-a-first-in-class-investigational-irak4-degrader/2462177/The first patient has been dosed in the Phase 2 clinical trial (ADVANTA) evaluating KT-474 in AD, generating a $15 million milestone payment under its collaboration with Sanofi. KT-474 is an oral IRAK4 degrader, in development for the treatment of IL-1R/TLR-driven complex inflamma
- Dial Gives Back to Teachers With DonorsChoose, TeacherListshttps://practicaldermatology.com/news/dial-gives-back-to-teachers-with-donorschoose-teacherlists/2462170/For the third consecutive year, Dial is partnering with DonorsChoose, an education-focused nonprofit that supports public sc
- Derm-Biome Pharmaceuticals, Massachusetts General Hospital Partner for Skin Cancer Study of New Topical Rxhttps://practicaldermatology.com/news/derm-biome-pharmaceuticals-massachusetts-general-hospital-partner-for-skin-cancer-study-of-new-topical-rx/2462157/Derm-Biome Pharmaceuticals Inc. is collaborating with Massachusetts General Hospital for a study looking at Derm-Biome’s second-generation topical treatment for precancerous skin conditions and non-melanoma skin cancers. The topical is highly sel
- AD Pipeline Watch: Oral Zelnecirnon Shows Early Promise in ADhttps://practicaldermatology.com/news/ad-pipeline-watch-oral-zelnecirnon-shows-early-promise-in-ad/2462153/Zelnecirnon performed well in a Phase 1a/1b clinical trial of atopic dermatitis (AD), RAPT Therapeutics reports. Zelnecirnon is a small molecule oral therapy designed to selectively inhibit the migration of Th2 cells into inflamed tissues by blocking CCR4, a receptor highly express
- Can a New Bacteriocin Thwart Antibiotic Resistance?https://practicaldermatology.com/news/can-a-new-bacteriocin-thwart-antibiotic-resistance/2462150/A new bacteriocin in a very common skin bacterium may inhibit the growth of antibiotic-resistant bacteria, new research suggests. The research group for child and youth health at UiT The Arctic University of Norway has studied bacter